MCID: CLS047
MIFTS: 33

Classic Progressive Supranuclear Palsy Syndrome

Categories: Eye diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Classic Progressive Supranuclear Palsy Syndrome

MalaCards integrated aliases for Classic Progressive Supranuclear Palsy Syndrome:

Name: Classic Progressive Supranuclear Palsy Syndrome 58
Steele-Richardson-Olszewski Disease 58
Progressive Supranuclear Palsy 71
Classic Psp Syndrome 58
Richardson Syndrome 58

Characteristics:


Age Of Onset:

Adult 58

Age Of Death:

elderly 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases


External Ids:

ICD10 via Orphanet 32 G23.1
UMLS via Orphanet 72 C0038868
Orphanet 58 ORPHA240071
UMLS 71 C0038868

Summaries for Classic Progressive Supranuclear Palsy Syndrome

Orphanet: 58 A classical form of progressive supranuclear palsy (PSP), a rare late-onset neurodegenerative disease, characterized by slowing of vertical saccadic eye movements, falls due to postural instability, axial akinetic-rigid syndrome, and cognitive impairment. Difficulties in speech and swallowing may develop.

MalaCards based summary: Classic Progressive Supranuclear Palsy Syndrome, also known as steele-richardson-olszewski disease, is related to atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease and noonan syndrome with multiple lentigines, and has symptoms including back pain, headache and muscle rigidity. An important gene associated with Classic Progressive Supranuclear Palsy Syndrome is MAPT (Microtubule Associated Protein Tau). The drugs Promethazine and Zolpidem have been mentioned in the context of this disorder. Affiliated tissues include eye, bone marrow and brain, and related phenotypes are postural instability and falls

Related Diseases for Classic Progressive Supranuclear Palsy Syndrome

Graphical network of the top 20 diseases related to Classic Progressive Supranuclear Palsy Syndrome:



Diseases related to Classic Progressive Supranuclear Palsy Syndrome

Symptoms & Phenotypes for Classic Progressive Supranuclear Palsy Syndrome

Human phenotypes related to Classic Progressive Supranuclear Palsy Syndrome:

58 30 (show all 28)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 postural instability 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002172
2 falls 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002527
3 dysarthria 58 30 Frequent (33%) Frequent (79-30%)
HP:0001260
4 photophobia 58 30 Frequent (33%) Frequent (79-30%)
HP:0000613
5 gait imbalance 58 30 Frequent (33%) Frequent (79-30%)
HP:0002141
6 blepharospasm 58 30 Frequent (33%) Frequent (79-30%)
HP:0000643
7 axial dystonia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002530
8 vertical supranuclear gaze palsy 58 30 Frequent (33%) Frequent (79-30%)
HP:0000511
9 impulsivity 58 30 Frequent (33%) Frequent (79-30%)
HP:0100710
10 bradykinesia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002067
11 slowed slurred speech 58 30 Frequent (33%) Frequent (79-30%)
HP:0007164
12 decreased lacrimation 58 30 Frequent (33%) Frequent (79-30%)
HP:0000633
13 blurred vision 58 30 Frequent (33%) Frequent (79-30%)
HP:0000622
14 slow saccadic eye movements 58 30 Frequent (33%) Frequent (79-30%)
HP:0000514
15 conjunctival hyperemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0030953
16 progressive extrapyramidal muscular rigidity 58 30 Frequent (33%) Frequent (79-30%)
HP:0007158
17 abnormal pyramidal sign 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0007256
18 tremor 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001337
19 akinesia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002304
20 parkinsonism with favorable response to dopaminergic medication 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002548
21 neuromuscular dysphagia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002068
22 social and occupational deterioration 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0007086
23 axial muscle stiffness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0006921
24 mental deterioration 58 Very frequent (99-80%)
25 dystonia 58 Occasional (29-5%)
26 parkinsonism 58 Frequent (79-30%)
27 supranuclear gaze palsy 58 Frequent (79-30%)
28 abnormal saccadic eye movements 58 Frequent (79-30%)

UMLS symptoms related to Classic Progressive Supranuclear Palsy Syndrome:


back pain; headache; muscle rigidity; ophthalmoplegia; pain; sciatica; seizures; syncope; tremor; photophobia; chronic pain; bradykinesia; poor mobility; vertigo/dizziness; forgetful; sleeplessness

Drugs & Therapeutics for Classic Progressive Supranuclear Palsy Syndrome

Drugs for Classic Progressive Supranuclear Palsy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Promethazine Approved, Investigational Phase 4 60-87-7 4927
2
Zolpidem Approved Phase 4 82626-48-0 5732
3
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
4
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
5
Zoledronic acid Approved Phase 4 118072-93-8 68740
6 Orexin Receptor Antagonists Phase 4
7 GABA Agonists Phase 4
8 Hypnotics and Sedatives Phase 4
9
Rivastigmine Approved, Investigational Phase 3 123441-03-2 77991
10
Riluzole Approved, Investigational Phase 3 1744-22-5 5070
11
Rasagiline Approved Phase 3 136236-51-6 3052776
12
Ubidecarenone Approved, Investigational, Nutraceutical Phase 2, Phase 3 303-98-0 5281915
13 Ubiquinone Phase 2, Phase 3
14 Micronutrients Phase 2, Phase 3
15 Vitamins Phase 2, Phase 3
16 Trace Elements Phase 2, Phase 3
17 Cholinesterase Inhibitors Phase 3
18 Cholinergic Agents Phase 3
19 Neurotransmitter Agents Phase 3
20 Protective Agents Phase 3
21 Neuroprotective Agents Phase 3
22 Anticonvulsants Phase 3
23 Excitatory Amino Acid Antagonists Phase 3
24 Monoamine Oxidase Inhibitors Phase 3
25
Donepezil Approved Phase 2 120014-06-4 3152
26
Lithium carbonate Approved Phase 1, Phase 2 554-13-2
27
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
28
Acetylcarnitine Approved, Investigational Phase 1, Phase 2 3040-38-8
29
Tolfenamic acid Approved, Investigational Phase 1, Phase 2 13710-19-5 610479
30
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
31
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
33
Lipoic acid Approved, Investigational, Nutraceutical Phase 1, Phase 2 1077-27-6, 1200-22-2 864 445125 6112
34
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium Experimental Phase 1, Phase 2 461-06-3
35
Fasudil Investigational Phase 2 103745-39-7 3547
36
Tilavonemab Investigational Phase 2 2096513-89-0
37 Antidepressive Agents Phase 1, Phase 2
38 Psychotropic Drugs Phase 1, Phase 2
39 Folate Phase 1, Phase 2
40 Vitamin B9 Phase 1, Phase 2
41 Vitamin B Complex Phase 1, Phase 2
42 Alpha-lipoic Acid Phase 1, Phase 2
43 Linoleate Phase 2
44 Protein Kinase Inhibitors Phase 2
45 Vasodilator Agents Phase 2
46 Calcium, Dietary Phase 1, Phase 2
47 Hormones Phase 1, Phase 2
48 calcium channel blockers Phase 1, Phase 2
49 Prostaglandin Antagonists Phase 1, Phase 2
50 Antirheumatic Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP) Recruiting NCT04014387 Phase 4 Suvorexant;Zolpidem;Placebo oral capsule
2 TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic Acid for the Prevention of Fractures in Patients With Parkinson's Disease Recruiting NCT03924414 Phase 4 Zoledronic Acid 5Mg/Bag 100Ml Inj
3 A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Completed NCT01110720 Phase 2, Phase 3 Davunetide;Placebo
4 A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls Completed NCT04193527 Phase 3 DaTSCAN™ Ioflupane (123I) Injection
5 Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study Completed NCT00532571 Phase 2, Phase 3 CoQ10
6 RIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical Trial Active, not recruiting NCT02839642 Phase 3 Rivastigmine;Placebo
7 Phase 3 Study of Riluzole in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP) (Parkinson's Plus Syndromes) Terminated NCT00211224 Phase 3 Riluzole
8 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III) Terminated NCT01187888 Phase 3 Rasagiline;Sugar pill
9 Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Unknown status NCT00139373 Phase 2 donepezil
10 Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial Unknown status NCT01824121 Phase 1, Phase 2
11 Rivastigmine (Exelon®) for Treatment of Dementia in Patient With Progressive Supranuclear Paresis Open Label Phase 2 Study Unknown status NCT00522015 Phase 2 rivastigmine
12 Mono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear Palsy Completed NCT00328874 Phase 2 Coenzyme Q10
13 A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Completed NCT00703677 Phase 1, Phase 2 Lithium
14 Randomized Placebo-controlled Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy Completed NCT00385710 Phase 2 valproic acid;Placebo
15 A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to Explore Efficacy and Safety of NBMI Treatment in Patients With Progressive Supranuclear Palsy (PSP) or Multiple System Atrophy (MSA) Completed NCT04184063 Phase 2 NBMI
16 An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers Completed NCT01537549 Phase 1, Phase 2 alpha-lipoic acid and L-acetyl carnitine
17 Dose-Escalation Trial of Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor for the Treatment of PSP Completed NCT00005903 Phase 2 GDNF & Synchro Med Infusion System
18 A Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Progressive Supranuclear Palsy Recruiting NCT04937530 Phase 2 RT001;Placebo
19 A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients With the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome. Active, not recruiting NCT04734379 Phase 2 Fasudil
20 A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) Active, not recruiting NCT04993768 Phase 2 TPN-101, 100 mg/day;TPN-101, 200 mg/day;TPN-101, 400 mg/day;Placebo
21 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy Active, not recruiting NCT04008355 Phase 2 AZP2006 oral solution;Placebo oral solution
22 A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Tolfenamic Acid for the Treatment of Progressive Supranuclear Palsy Not yet recruiting NCT04253132 Phase 1, Phase 2 Tolfenamic Acid;Placebos
23 A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy Terminated NCT02985879 Phase 2 Placebo;ABBV-8E12
24 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy Terminated NCT03068468 Phase 2 BIIB092;Placebo
25 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Terminated NCT03391765 Phase 2 ABBV-8E12;Placebo solution for IV infusion on Day 15
26 Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Withdrawn NCT03446807 Phase 2 Droxidopa;Placebo Oral Tablet
27 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy Completed NCT02133846 Phase 1 TPI 287 2 mg/m2;TPI-287 20 mg/m2;Placebo;TPI-287 6.3 mg/m2
28 18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers Completed NCT02167594 Phase 1 Flortaucipir F18
29 A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) Completed NCT04185415 Phase 1 bepranemab;Placebo
30 A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Completed NCT02422485 Phase 1 Salsalate
31 Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Completed NCT03413319 Phase 1 ABBV-8E12
32 A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy Completed NCT02460094 Phase 1 BIIB092;Placebo
33 A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy Completed NCT02460731 Phase 1
34 A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Completed NCT02494024 Phase 1 Single dose C2N-8E12;Single dose placebo
35 A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies Completed NCT01056965 Phase 1 davunetide (AL-108, NAP);Placebo nasal spray
36 Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects Completed NCT02103894 Phase 1 [18F]T807 ([18F]MNI-777)
37 Phase 1 Test-retest Evaluation of [18F]MNI-958 PET as an Imaging Marker for Tau Protein in the Brain of Patients With Alzheimer's Disease and Probable PSP as Compared to Healthy Volunteers Completed NCT03545789 Phase 1 [18F]MNI-958
38 Evaluation of [18F]APN-1607 as a PET Biomarker for Longitudinal Change in Tau Pathology in Participants With Progressive Supranuclear Palsy Recruiting NCT05005819 Phase 1 [18F] APN-1607
39 An Open Label, Single Center Study to Evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Mild to Moderate Alzheimer's Disease (AD) and Patients With Progressive Supranuclear Palsy (PSP) After i.v. Application of [18F]PI-2620 With High and Low Specific Activity Recruiting NCT04715750 Phase 1 [18F]-PI2620
40 An Open Label, Single Center Study to Evaluate the Safety and Test-retest Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau Deposition in the Brains of Patients With Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) Compared to Non-demented Controls (NDC) Recruiting NCT05187546 Phase 1 [18F]-PI2620
41 A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy Recruiting NCT04539041 Phase 1 antisense oligonucleotide;placebo
42 An Open-Label Extension Study to Evaluate the Safety and Tolerability of Long-Term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Active, not recruiting NCT04658199 Phase 1 UCB0107 (bepranemab)
43 A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003 Terminated NCT02658916 Phase 1 BIIB092
44 Cross-sectional Study of the Factors Determining the Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy Unknown status NCT03638505
45 Functional Assessment of the Melanopsin-Containing Retinal Ganglion Cells in Progressive Supranuclear Palsy Using Chromatic Pupillometry Unknown status NCT03330353
46 Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration Unknown status NCT01804452
47 A Multi-centre Proof-of-performance Clinical Study to Validate Blood-based Biomarker Candidates for the Diagnosis of Alzheimer's Disease Unknown status NCT03030586
48 Multimodal Assessment For Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration Unknown status NCT02964637
49 Blood Alpha-Synuclein, Gene Expression, and Smell Testing as Diagnostic and Prognostic Biomarkers in Parkinson's Disease Unknown status NCT00653783
50 Statistical Mapping of the Brain in Progressive Supranuclear Palsy, Essential Tremor, Parkinson Disease, Parkinsonism, and REM Behavior Disorder Completed NCT01547481

Search NIH Clinical Center for Classic Progressive Supranuclear Palsy Syndrome

Genetic Tests for Classic Progressive Supranuclear Palsy Syndrome

Anatomical Context for Classic Progressive Supranuclear Palsy Syndrome

Organs/tissues related to Classic Progressive Supranuclear Palsy Syndrome:

MalaCards : Eye, Bone Marrow, Brain, Spinal Cord, Cortex, Skin, Bone

Publications for Classic Progressive Supranuclear Palsy Syndrome

Articles related to Classic Progressive Supranuclear Palsy Syndrome:

(show top 50) (show all 86)
# Title Authors PMID Year
1
Deciphering the saccade velocity profile of progressive supranuclear palsy: A sign of latent cerebellar/brainstem dysfunction? 62
33632587 2022
2
Interplay of tau and functional network connectivity in progressive supranuclear palsy: a [18F]PI-2620 PET/MRI study. 62
36048259 2022
3
A Machine Learning-Based Approach to Discrimination of Tauopathies Using [18 F]PM-PBB3 PET Images. 62
36054492 2022
4
Protracted course progressive supranuclear palsy. 62
35384155 2022
5
The Significance of Asymmetry in the Assessment of Brain Perfusion in Atypical Tauopathic Parkinsonian Syndromes. 62
35885575 2022
6
Differential diagnosis between Parkinson's disease and atypical parkinsonism based on gait and postural instability: Artificial intelligence using an enhanced weight voting ensemble model. 62
35447488 2022
7
Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. 62
35486397 2022
8
Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant. 62
35597031 2022
9
Perspective: Balance Assessments in Progressive Supranuclear Palsy: Lessons Learned. 62
35153996 2022
10
A data-driven model of brain volume changes in progressive supranuclear palsy. 62
35602649 2022
11
Clinical Spectrum of Tauopathies. 62
35911892 2022
12
Is the Phenotype Designation by PSP-MDS Criteria Stable Throughout the Disease Course and Consistent With Tau Distribution? 62
35185775 2022
13
"Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism. 62
34532773 2021
14
Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. 62
34021393 2021
15
Sleep disturbances in the speech-language variant of progressive supranuclear palsy. 62
34425331 2021
16
Association Between Globular Glial Tauopathies and Frontotemporal Dementia-Expanding the Spectrum of Gliocentric Disorders: A Review. 62
34152367 2021
17
Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy. 62
33822892 2021
18
A novel diagnostic marker for progressive supranuclear palsy targeting atrophy of the subthalamic nucleus. 62
33714084 2021
19
Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy. 62
33744691 2021
20
Abnormal structural connectivity in progressive supranuclear palsy-Richardson syndrome. 62
33175396 2021
21
Eye movements and association with regional brain atrophy in clinical subtypes of progressive supranuclear palsy. 62
32959131 2021
22
Neutrophil-to-lymphocyte ratio (NLR) at boundaries of Progressive Supranuclear Palsy Syndrome (PSPS) and Corticobasal Syndrome (CBS). 62
33315235 2021
23
Progressive Supranuclear Palsy and Corticobasal Degeneration. 62
33433875 2021
24
Segmental Alterations of the Corpus Callosum in Progressive Supranuclear Palsy: A Multiparametric Magnetic Resonance Imaging Study. 62
34867268 2021
25
Severity of Downgaze Palsy in the Context of Disease Duration Could Estimate Survival Duration in Patients With Progressive Supranuclear Palsy. 62
34650511 2021
26
Pedunculopontine Nucleus Deep Brain Stimulation for Parkinsonian Disorders: A Case Series. 62
33279909 2021
27
Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. 62
33165511 2020
28
Suicidal and death ideation in patients with progressive supranuclear palsy and corticobasal syndrome. 62
32768878 2020
29
MDS criteria for the diagnosis of progressive supranuclear palsy overemphasize Richardson syndrome. 62
32735745 2020
30
A Convenient Prognostic Tool and Staging System for Progressive Supranuclear Palsy. 62
32775512 2020
31
Distribution patterns of tau pathology in progressive supranuclear palsy. 62
32383020 2020
32
The Non-Motor Symptom Profile of Progressive Supranuclear Palsy. 62
32241079 2020
33
Gradient subthalamic neurodegeneration and tau pathology in the hypoglossal nucleus as essential pathological markers of progressive supranuclear palsy - Richardson syndrome. 62
32247606 2020
34
Alien limb in the corticobasal syndrome: phenomenological characteristics and relationship to apraxia. 62
31919566 2020
35
Magnetic Resonance Parkinsonism Index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study. 62
32036297 2020
36
Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. 62
31860007 2020
37
Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting. 62
34316619 2020
38
Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale. 62
33789283 2020
39
Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. 62
31433871 2019
40
[Progressive supranuclear palsy-Richardson syndrome with visual attention disturbance (Holmes and Horrax) and ataxie optique (Garcin): a case report]. 62
31656263 2019
41
Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability. 62
31307919 2019
42
Factors that predict diagnostic stability in neurodegenerative dementia. 62
31102021 2019
43
Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. 62
30598430 2019
44
Atrophy in midbrain & cerebral/cerebellar pedunculi is characteristic for progressive supranuclear palsy - A double-validation whole-brain meta-analysis. 62
30831462 2019
45
"Feasibility and utility of a simple computerized test for measuring saccade latency in progressive supranuclear palsy- a proof-of-concept study". 62
31844536 2019
46
Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. 62
30066433 2018
47
Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. 62
29958546 2018
48
[11C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy. 62
29703774 2018
49
Progressive Supranuclear Palsy: an Update. 62
29455271 2018
50
A Fully Automated, Atlas-Based Approach for Superior Cerebellar Peduncle Evaluation in Progressive Supranuclear Palsy Phenotypes. 62
28034996 2017

Variations for Classic Progressive Supranuclear Palsy Syndrome

Expression for Classic Progressive Supranuclear Palsy Syndrome

Search GEO for disease gene expression data for Classic Progressive Supranuclear Palsy Syndrome.

Pathways for Classic Progressive Supranuclear Palsy Syndrome

GO Terms for Classic Progressive Supranuclear Palsy Syndrome

Sources for Classic Progressive Supranuclear Palsy Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....